HI HB667

Requires patients and prescribers to execute a written informed consent agreement for opioid therapy when treatment exceeds three months, involves concurrent benzodiazepines, or exceeds 90 morphine equivalent doses.

Mandates the informed consent template include discussions of overdose risks, naloxone co-prescribing, non-opioid alternatives, functional treatment goals, risk assessments, urine drug screening at initiation and at least twice yearly, and psychiatric referral if therapy continues beyond six months.

Limits initial opioid and benzodiazepine prescriptions to a maximum of seven consecutive days, with exceptions allowed for cancer pain, palliative care, and hospice care when documented in the patient's medical record.

Requires prescribers issuing exceptions to document the medical condition and that non-opioid alternatives are inappropriate for that condition.

Effective July 1, 2090.